Form 4: IGM Biosciences Director Jakob Haldor Topsoe Acquires Shares Through RSU Grant

IGM Biosciences, Inc. Director and 10% owner Jakob Haldor Topsoe acquired 828 shares of common stock on June 30, 2025, as part of a quarterly retainer in fully vested restricted stock units.

Summary

• Jakob Haldor Topsoe, a Director and 10% owner of IGM Biosciences, Inc., acquired 828 shares of common stock.
• The transaction occurred on June 30, 2025.
• These shares were acquired as fully vested restricted stock units (RSUs) with a price of $0.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• This acquisition reflects the payment of a quarterly retainer in common stock, consistent with the Issuer's Outside Director Compensation Policy.
• Following this transaction, Jakob Haldor Topsoe directly beneficially owns 91,712 shares and indirectly beneficially owns 10,400,564 shares.
• The indirect shares are held by Topsoe Holding A/S, where Jakob Haldor Topsoe and other board members may share voting and investment power, disclaiming beneficial ownership except for their pecuniary interest.

Sentiment

Score: 6

Explanation: The transaction is a routine RSU grant as part of director compensation, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not indicate any significant operational or financial changes, hence a neutral-to-slightly-positive score.

Positives

• Acquisition of shares by a director and 10% owner indicates continued alignment of interests with shareholders.
• The transaction is part of a standard compensation policy (quarterly retainer), reflecting routine corporate governance.

Negatives

• No negative aspects are indicated by this routine compensation-related transaction.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to director compensation, which is common across industries for publicly traded companies. It does not provide specific insights into broader industry trends for biotechnology or pharmaceuticals, beyond the standard practice of equity-based compensation for directors.

Comparison to Industry Standards

• This transaction, being a grant of restricted stock units as part of director compensation, aligns with common industry practices for public companies, including those in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, or Biogen often use similar equity-based compensation structures for their board members to align their interests with long-term shareholder value.
• The specific amount of shares granted would be determined by the company's compensation policy and the director's role, but the mechanism itself is standard.

Related Party Transactions

• The indirect beneficial ownership of 10,400,564 shares by Topsoe Holding A/S, where Jakob Haldor Topsoe is a board member, represents a related party holding.
• The transaction itself (acquisition of 828 shares) is a direct grant to Jakob Haldor Topsoe as compensation, not a transaction with Topsoe Holding A/S.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns the director's interests with shareholders, potentially fostering long-term value creation. The dilution from 828 shares is negligible.
• Employees, Customers, Suppliers, Creditors: No direct impact indicated by this specific transaction.

Key Dates

Keywords

IGM Biosciences, IGMS, Jakob Haldor Topsoe, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, 10% Owner